Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I11/701

[1] 中华人民共和国国家卫生和计划生育委员会.药品不良反应报告和监测管理办法[EB/OL].(2011-05-04)[2017-03-29]. http://www.moh.gov.cn/mohzcfgs/pgz/201105/51770.shtml.
[2] 段砺瑕,李晓玲.氟比洛芬酯注射液的药理作用及临床应用[J].中国新药杂志,2004,13(9):851-852.
[3] 高凯,王晓飞,王苗,等.氟比洛芬酯用于骨科手术超前镇痛的效果及不良反应观察[J].陕西医学杂志,2016,45(1)：78-80.
[4] Alvira Jfar Cahowdhury,王瑞伟,王公明,等. 氟比洛芬酯超前镇痛复合不同剂量舒芬太尼对小儿骨盆截骨矫形术后镇痛效果的比较[J]. 齐鲁医学杂志,2017,32(1):51-53.
[5] 贾秀眉,兰丽琴,汤礼贵. 氟比洛芬酯对骨科手术超前镇痛及术后镇痛的临床疗效评价[J]. 中国临床药理学杂志,2016,32(2):150-152.
[6] 韩斌,赵国胜.氟比洛芬酯的临床应用进展[J].中国误诊学杂志,2011,11(7):1529-1530.
[7] 付志强,吕国义,邓封.氟比洛芬酯的药理及临床应用[J].中日友好医院学报,2007,21(3):178-180.
[8] 陈集志,李刚,徐江红,等.住院患者应用氟比洛芬酯注射液回顾性分析[J].中国药师,2012,15(4):542-544.
[9] 贾慧,裴凌.氟比洛芬酯临床镇痛效果和安全性的Meta分析[J].中国循证医学杂志,2011,11(12):1409-1418.
[10] 沈珠,曹国文,鲍君杰,等.氟比洛芬酯的超说明书及不合理用药分析[J].中国医院药学杂志,2016,36(10):844-847.
[11] 倪晓 ,钟晗,刘晓琰.氟比洛芬酯注射液致癫痫发作1例[J].中国药物警戒,2012,9(7):443.
[12] 卜艳丽,王晨.氟比洛芬酯所致癫痫样发作文献概述[J].中国药物滥用防治杂志,2015,21(2):118.
[13] 赵琴,陶宜富,朱余兵,等.氟比洛芬酯与帕瑞昔布镇痛效果对比及术后疼痛高危因素调查[J].中国药师,2013,16(8):1189-1192.
[14] Zhu T H,Chen S H,Li W Y,etal．Flurbiprofen axetil loaded coaxial electrospun poly(vinyl pyrro1idone)-nanopoly(1actic-co-glycolic acid) core-shell composite nanofibers：Preparation,characterization,and anti-adhesion activity[J].Journal of Applied Polymer Science,2015,132(22):419-428．
[15] 国家风湿病数据中心,中国系统性红斑狼疮研究协作组.非甾体消炎药相关消化道溃疡与溃疡并发症的预防与治疗规范建议[J].中华内科杂志,2017,56(1)：81-85.
[16] Svensson C I, Yaksh T L.The spinal phospholipasecyclooxyge-nase-Prostanoid cascade in nociceptive processing [J].AnnRev Pharmacol Toxicol , 2002,42：553-583.
[17] 甄细娥,王宽,宗鸣,等.降低非甾体抗炎药致胃肠道不良反应的方法研究进展[J].中国药房,2013,24(10):935-938.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.